Brains to go public via SPAC merger at $750M valuation
What's the deal? Armada Acquisition Corp. IIIDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed special purpose acquisition company, has agreed to merge with Brains Bioceutical Corp., a cannabinoid-focused pharmaceutical company. The combined business will operate as Brains Therapeutics Corp. and trade on the Nasdaq under the ticker "BAPI". The deal values Brains at an implied pre-money equity value of roughly $750 million.
What does Brains do? The company manufactures and supplies active pharmaceutical ingredients (APIs), focused on pharmaceutical-grade cannabinoids. Through its subsidiary BSPG Laboratories, it runs what it calls one of the world's largest cannabinoid API manufacturing facilities, producing ingredients such as CBD, THC, CBN, and CBG.
What's the endgame? Brains pairs European EU-GMP manufacturing with a portfolio of proprietary and partnered drug programs targeting glaucoma and epilepsy. It also supplies clinical trial material for an opioid use disorder program, and extends its ingredient platform into supplements, beverages, personal care, and animal health.
Why now? The deal taps renewed use of SPACs to bring life-sciences firms to the Nasdaq. Recent announced combinations include TriGemX Bio's roughly $600 million deal and Corxel's planned merger, which carries about $300 million in PIPE financing.
What could go wrong? This is a planned combination, not a completed one, with closing expected in the second quarter of 2027, subject to approvals. The announcement does not cite committed PIPE funding, so available cash may hinge on the SPAC trust balance and shareholder redemptions. Regulation adds risk: the US Food and Drug Administration recently said CBD products need a new regulatory pathway and declined to allow them as supplements or foods under existing rules.
The signal: SPACs are back as a route to public markets for life-sciences companies, but the structure leaves the final cash haul uncertain. For Brains, a Nasdaq listing offers scale — if the deal clears and regulators warm to cannabinoid medicines.
Read more: marketscreener.com
Image credit: Generated with Gemini
